DCm@NPs can mimic APCs and promote the differentiation of CD4+/CD8+ T cells; Tm@NPs can bind to immunosuppressive molecules (e.g., TGF-β) and PD-L1 on tumor cells, effectively restoring T cells’ cancer-killing capabilities. Here, CD8A is linked to neoplasm.